U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07246707) titled 'KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia' on Nov. 17.
Brief Summary: This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 injection for patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
B-ALL
Intervention:
DRUG: KSV01 Injection
KSV01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector.
Recruitment Status: RECRUITING
Sponsor: Zhejiang Unive...